When tested in the human gastric cancer AGS cell line and human pancreatic cancer ASPC-1 cell line carrying the KRAS-G12D mutation, the two PROTACs did not exhibit significant advantages over the inhibitor 10k and the positive control drug MRTX1133. This evidence concerns the gene KRAS and familial pancreatic carcinoma.